CO4750819A1 - Procedimientos para inhibir el inhibidor del activador del plasminogeno 1 - Google Patents

Procedimientos para inhibir el inhibidor del activador del plasminogeno 1

Info

Publication number
CO4750819A1
CO4750819A1 CO96053493A CO96053493A CO4750819A1 CO 4750819 A1 CO4750819 A1 CO 4750819A1 CO 96053493 A CO96053493 A CO 96053493A CO 96053493 A CO96053493 A CO 96053493A CO 4750819 A1 CO4750819 A1 CO 4750819A1
Authority
CO
Colombia
Prior art keywords
plasminogen activator
activator inhibitor
inhibiting
procedures
hexamitilenimino
Prior art date
Application number
CO96053493A
Other languages
English (en)
Inventor
David Thompson Berg
Mark Alan Richardson
Brian William Grinnell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4750819A1 publication Critical patent/CO4750819A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

El uso de un compuesto de fórmula (I):en la que R1 y R3 son independientemente hidrógeno, o o ¦ ¦ ¦ ¦CH3 , -C-(alquilo de C1 -C6 ), o -C-Ar, en el que Ar es fenilo opcionalmente sustituido; R2 se selecciona entre el grupo compuesto por pirrolidino, hexamitilenimino y piperidino; o una de sus sales o solvatos farmacéuticamente aceptables en la preparación de un medicamento útil para inhibir el inhibidor del activador de plasminógeno 1.
CO96053493A 1995-10-10 1996-10-08 Procedimientos para inhibir el inhibidor del activador del plasminogeno 1 CO4750819A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US501595P 1995-10-10 1995-10-10

Publications (1)

Publication Number Publication Date
CO4750819A1 true CO4750819A1 (es) 1999-03-31

Family

ID=21713702

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96053493A CO4750819A1 (es) 1995-10-10 1996-10-08 Procedimientos para inhibir el inhibidor del activador del plasminogeno 1

Country Status (20)

Country Link
US (1) US5731328A (es)
EP (1) EP0854715B1 (es)
JP (1) JPH11513665A (es)
KR (1) KR19990064099A (es)
CN (1) CN1199337A (es)
AR (1) AR003812A1 (es)
AT (1) ATE255414T1 (es)
AU (1) AU716655B2 (es)
CA (1) CA2234404A1 (es)
CO (1) CO4750819A1 (es)
CZ (1) CZ106098A3 (es)
DE (1) DE69630969T2 (es)
EA (1) EA001003B1 (es)
ES (1) ES2211981T3 (es)
HU (1) HUP9802348A3 (es)
NO (1) NO981578D0 (es)
NZ (1) NZ319948A (es)
PL (1) PL326294A1 (es)
WO (1) WO1997013511A1 (es)
ZA (1) ZA968444B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
US5792798A (en) * 1996-07-29 1998-08-11 Eli Lilly And Company Method for inhibiting plasminogen activator inhibitor 1
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
AU2001249670A1 (en) * 2000-04-03 2001-10-15 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
WO2006088011A1 (ja) * 2005-02-15 2006-08-24 Tokai University Educational System プラスミノーゲンアクチベーターインヒビター－１阻害剤
US8066991B2 (en) * 2005-10-11 2011-11-29 Amano Enzyme Usa Co., Ltd. Enzyme inhibitors of PAI-1
CN101544138B (zh) * 2008-03-26 2012-05-23 山东新北洋信息技术股份有限公司 热转印打印机碳带回收装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
DE69433578T2 (de) * 1993-12-21 2004-12-16 Eli Lilly And Co., Indianapolis Hemmung der Endprodukte fortgeschrittener Glykolisierung

Also Published As

Publication number Publication date
WO1997013511A1 (en) 1997-04-17
CA2234404A1 (en) 1997-04-17
EP0854715A1 (en) 1998-07-29
DE69630969T2 (de) 2004-10-21
ES2211981T3 (es) 2004-07-16
JPH11513665A (ja) 1999-11-24
CN1199337A (zh) 1998-11-18
EA199800366A1 (ru) 1998-10-29
ATE255414T1 (de) 2003-12-15
EP0854715A4 (en) 2001-12-19
AU7259696A (en) 1997-04-30
NO981578L (no) 1998-04-07
NZ319948A (en) 2000-06-23
AR003812A1 (es) 1998-09-09
CZ106098A3 (cs) 1999-03-17
AU716655B2 (en) 2000-03-02
EP0854715B1 (en) 2003-12-03
HUP9802348A3 (en) 1999-11-29
EA001003B1 (ru) 2000-08-28
US5731328A (en) 1998-03-24
NO981578D0 (no) 1998-04-07
PL326294A1 (en) 1998-09-14
DE69630969D1 (de) 2004-01-15
ZA968444B (en) 1998-04-07
KR19990064099A (ko) 1999-07-26
HUP9802348A2 (hu) 1999-08-30

Similar Documents

Publication Publication Date Title
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
LU91497I2 (fr) Rivaroxaban et ses sels pharmaceutiquement acceptables,hydrates,hydrates de ces sels et promédicaments
CR10145A (es) Derivados de tropano útiles en terapia (divisional exp. 6800)
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
CO4700421A1 (es) Compuestos de naftilo, intermedios, composiciones y procedimientos
AR003930A1 (es) Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados
NO944930L (no) Hemming av dysfunksjonell uterin blödning
ES2101449T3 (es) Inhibicion de la seborrea y el acne.
CO4750819A1 (es) Procedimientos para inhibir el inhibidor del activador del plasminogeno 1
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
ATE229800T1 (de) Guanidino proteiase inhibitoren
CO4650039A1 (es) Benzotiofenos amorfos, procedimientos de preparacion y procedimientos de uso
ECSP941050A (es) Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contiene
CO5280088A1 (es) Inhibidores de proteasa
ES2182090T3 (es) Nuevos derivados de pirrol.
PE20001355A1 (es) 1,3-diamino-cetonas como inhibidores de proteasas
DE69422629T2 (de) Indolderivate als 5-alpha-reductase-1 inhibitoren
DE69405760T2 (de) 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
AR027035A1 (es) Pirroles sustituidos
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
ECSP961892A (es) Procedimientos para inhibir el inhibidor del activador del plasminogeno 1
YU6996A (sh) Upotreba benzotiofena za dobijanje leka
AR001768A1 (es) Derivados de ciclolignano utiles como antineoplasicos composiciones farmaceuticas que los contienen y proceso para preparar dichos derivados
ECSP972238A (es) Benzotiofenos amorfos, procedimientos para su preparacion y procedimiento para su uso